Menu
Search
|

Menu

Close
X

Citius Pharmaceuticals Inc CTXR.OQ (NASDAQ Stock Exchange Capital Market)

3.60 USD
+0.00 (+0.00%)
As of 2:29 AM IST
chart
Previous Close 3.60
Open 3.52
Volume 4,163
3m Avg Volume 21,938
Today’s High 3.60
Today’s Low 3.50
52 Week High 5.46
52 Week Low 0.34
Shares Outstanding (mil) 8.25
Market Capitalization (mil) 26.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 1 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.931
FY16
-2.159
FY15
-1.363
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
1.38
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
46.72
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-66.76
14.43
Return on Equity (TTM)
vs sector
-66.76
16.13

EXECUTIVE LEADERSHIP

Leonard Mazur
Executive Chairman of the Board, Secretary, Since 2016
Salary: $250,000.00
Bonus: $120,000.00
Myron Holubiak
President, Chief Executive Officer, Director, Since 2016
Salary: $225,000.00
Bonus: $112,500.00
Jaime Bartushak
Chief Financial Officer, Principal Financial Officer, Since 2017
Salary: --
Bonus: --
Suren Dutia
Director, Since 2015
Salary: --
Bonus: --
Eugene Holuka
Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

11 Commerce Dr Fl 1
CRANFORD   NJ   07016-3501

Phone: +1908.9676676

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortisone-Lidocaine Cream. The Company's Mino-Lok is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. The Company's Hydrocortisone-Lidocaine topical formulation provides anti-inflammation and anesthetic relief to persons suffering from hemorrhoids. Its Mino-Lok product for the treatment of catheter related bloodstream infections has completed Phase IIb and is entering Phase III trials. It is reformulating Hydrocortisone-Lidocaine product and will be entering Phase IIb trials in 2017. As of September 30, 2016, the Company had not generate any revenues.

SPONSORED STORIES